JP Morgan Chase
BCYC

JP Morgan Chase’s Bicycle Therapeutics BCYC Stock Holding History

JP Morgan Chase’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.2K Buy
13,056
+3,183
+32% +$14.6K ﹤0.01% 6387
2026
Q1 		$42.8K Sell
9,873
-8,482
-46% -$48.5K ﹤0.01% 6256
2025
Q4 		$130K Buy
18,355
+10,228
+126% +$75.4K ﹤0.01% 5755
2025
Q3 		$62.9K Buy
8,127
+490
+6% +$3.7K ﹤0.01% 6141
2025
Q2 		$53.1K Buy
7,637
+593
+8% +$4.72K ﹤0.01% 5905
2025
Q1 		$59.8K Sell
7,044
-663
-9% -$7.81K ﹤0.01% 5805
2024
Q4 		$108K Sell
7,707
-717
-9% -$15.4K ﹤0.01% 5728
2024
Q3 		$191K Buy
8,424
+1,782
+27% +$41.1K ﹤0.01% 5425
2024
Q2 		$134K Sell
6,642
-8,946
-57% -$202K ﹤0.01% 5370
2024
Q1 		$388K Buy
15,588
+5,482
+54% +$116K ﹤0.01% 4960
2023
Q4 		$183K Sell
10,106
-58,393
-85% -$966K ﹤0.01% 5433
2023
Q3 		$1.38M Sell
68,499
-27,652
-29% -$632K ﹤0.01% 3844
2023
Q2 		$2.45M Buy
96,151
+9,013
+10% +$209K ﹤0.01% 3386
2023
Q1 		$1.85M Buy
87,138
+3,932
+5% +$98.6K ﹤0.01% 3596
2022
Q4 		$2.46M Sell
83,206
-42,483
-34% -$1.14M ﹤0.01% 3404
2022
Q3 		$2.92M Buy
125,689
+42,231
+51% +$1M ﹤0.01% 3165
2022
Q2 		$1.4M Buy
83,458
+73,555
+743% +$1.55M ﹤0.01% 3837
2022
Q1 		$434K Buy
9,903
+7,075
+250% +$330K ﹤0.01% 4789
2021
Q4 		$172K Buy
2,828
+1,463
+107% +$80.7K ﹤0.01% 5433
2021
Q3 		$57K Sell
1,365
-691
-34% -$24.2K ﹤0.01% 5791
2021
Q2 		$63K Buy
2,056
+754
+58% +$22.8K ﹤0.01% 5672
2021
Q1 		$39K Buy
+1,302
New +$33.6K ﹤0.01% 5587

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

JP Morgan Chase's BCYC Position: Q2 2026 in Review

JP Morgan Chase increased its Bicycle Therapeutics (BCYC) stake by 32% in Q2 2026, buying an estimated $14.6K and bringing the position to 13,056 shares worth $54.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6387.

JP Morgan Chase first reported a position in BCYC in Q1 2021 and has held it in 22 quarters since. The position peaked at $2.92M in Q3 2022. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • JP Morgan Chase held 13,056 shares of Bicycle Therapeutics worth $54.2K as of Q2 2026.
  • JP Morgan Chase bought 3,183 Bicycle Therapeutics shares in Q2 2026, an estimated $14.6K.
  • Bicycle Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6387 holding.
  • JP Morgan Chase first reported a position in Bicycle Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • JP Morgan Chase's Bicycle Therapeutics position peaked at $2.92M in Q3 2022.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.